AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lantern Pharma Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors
ByAinvest
Thursday, Nov 20, 2025 8:35 pm ET1min read
Lantern Pharma Inc. (LTRN) presented Phase 1a clinical results for LP-184, a drug aimed at treating advanced solid tumors, particularly those deficient in DNA damage repair mechanisms. The company discussed the molecule's scientific background, clinical trial results, and implications for the treatment of DNA damage repair-deficient tumors. The webinar featured company participants, including CEO Panna Sharma, Chief Scientific Officer Kishor Bhatia, and Head of Clinical Development Reggie Ewesuedo, as well as collaborator Dr. Igor Astsaturov from Fox Chase.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet